Literature DB >> 20470215

CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system.

William R Hartman1, Linda L Pelleymounter, Irene Moon, Krishna Kalari, Mohan Liu, Tse-Yu Wu, Carlos Escande, Veronica Nin, Eduardo N Chini, Richard M Weinshilboum.   

Abstract

CD38 is an ecto-enzyme that hydrolyzes NAD. Its expression is a prognostic marker for chronic lymphocytic leukemia. We have characterized individual variation in CD38 expression in lymphoblastoid cell lines from 288 healthy subjects of three ethnicities. Expression varied widely, with significant differences among ethnic groups, and was correlated significantly with CD38 enzymatic activity and protein levels. The CD38 gene was then resequenced using DNA from the same cell lines, with the identification of 53 single nucleotide polymorphisms (SNPs) and one indel, 39 novel. One SNP, rs1130169, was significantly associated with CD38 mRNA expression and explained a portion of the difference in expression among ethnic groups. EMS assay showed nuclear protein binding at or near this SNP. We also determined that variation in CD38 expression in these cell lines was associated with variation in antineoplastic drug sensitivity. These results represent a step toward understanding mechanisms involved in CD38 expression.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470215      PMCID: PMC2892000          DOI: 10.3109/10428194.2010.483299

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  28 in total

1.  CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease.

Authors:  Terry J Hamblin; Jenny A Orchard; Rachel E Ibbotson; Zadie Davis; Peter W Thomas; Freda K Stevenson; David G Oscier
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL.

Authors:  B T Pittner; D F Jelinek; N E Kay
Journal:  Leukemia       Date:  2004-01       Impact factor: 11.528

3.  Natural variation in human gene expression assessed in lymphoblastoid cells.

Authors:  Vivian G Cheung; Laura K Conlin; Teresa M Weber; Melissa Arcaro; Kuang-Yu Jen; Michael Morley; Richard S Spielman
Journal:  Nat Genet       Date:  2003-02-03       Impact factor: 38.330

Review 4.  Reconstructing eukaryotic NAD metabolism.

Authors:  Anthony Rongvaux; Fabienne Andris; Frédéric Van Gool; Oberdan Leo
Journal:  Bioessays       Date:  2003-07       Impact factor: 4.345

Review 5.  NAD+ surfaces again.

Authors:  Mathias Ziegler; Marc Niere
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

6.  A gene expression database for the molecular pharmacology of cancer.

Authors:  U Scherf; D T Ross; M Waltham; L H Smith; J K Lee; L Tanabe; K W Kohn; W C Reinhold; T G Myers; D T Andrews; D A Scudiero; M B Eisen; E A Sausville; Y Pommier; D Botstein; P O Brown; J N Weinstein
Journal:  Nat Genet       Date:  2000-03       Impact factor: 38.330

7.  Statistical method for testing the neutral mutation hypothesis by DNA polymorphism.

Authors:  F Tajima
Journal:  Genetics       Date:  1989-11       Impact factor: 4.562

Review 8.  NAADP-induced calcium release in sea urchin eggs.

Authors:  A Galione; S Patel; G C Churchill
Journal:  Biol Cell       Date:  2000-07       Impact factor: 4.458

9.  Genetic analysis of genome-wide variation in human gene expression.

Authors:  Michael Morley; Cliona M Molony; Teresa M Weber; James L Devlin; Kathryn G Ewens; Richard S Spielman; Vivian G Cheung
Journal:  Nature       Date:  2004-07-21       Impact factor: 49.962

Review 10.  Dynamics of the p53 acetylation pathway.

Authors:  Wei Gu; Jianyuan Luo; Chris L Brooks; Anatoly Y Nikolaev; Muyang Li
Journal:  Novartis Found Symp       Date:  2004
View more
  9 in total

1.  Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.

Authors:  Claudia C S Chini; Anatilde M Gonzalez Guerrico; Veronica Nin; Juliana Camacho-Pereira; Carlos Escande; Maria Thereza Barbosa; Eduardo N Chini
Journal:  Clin Cancer Res       Date:  2013-09-11       Impact factor: 12.531

2.  Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation.

Authors:  Naveen L Pereira; Pinar Aksoy; Irene Moon; Yi Peng; Margaret M Redfield; John C Burnett; Eric D Wieben; Vivien C Yee; Richard M Weinshilboum
Journal:  J Mol Cell Cardiol       Date:  2010-08-06       Impact factor: 5.000

3.  T-lymphocyte activation markers in patients with HIV-1-associated neurocognitive disorder.

Authors:  Claudete M S Ferreira; Noemia M O Sunada; Jorge Casseb
Journal:  J Neurovirol       Date:  2022-05-08       Impact factor: 3.739

4.  Fh15 Blocks the Lipopolysaccharide-Induced Cytokine Storm While Modulating Peritoneal Macrophage Migration and CD38 Expression within Spleen Macrophages in a Mouse Model of Septic Shock.

Authors:  Marcos J Ramos-Benitez; Caleb Ruiz-Jimenez; Jose J Rosado-Franco; Willy D Ramos-Pérez; Loyda B Mendez; Antonio Osuna; Ana M Espino
Journal:  mSphere       Date:  2018-12-19       Impact factor: 4.389

Review 5.  NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer.

Authors:  Valentina Audrito; Antonella Managò; Federica Gaudino; Leonardo Sorci; Vincenzo Gianluca Messana; Nadia Raffaelli; Silvia Deaglio
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

6.  In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma.

Authors:  David T Omstead; Franklin Mejia; Jenna Sjoerdsma; Baksun Kim; Jaeho Shin; Sabrina Khan; Junmin Wu; Tanyel Kiziltepe; Laurie E Littlepage; Basar Bilgicer
Journal:  J Hematol Oncol       Date:  2020-11-02       Impact factor: 17.388

Review 7.  The Extracellular NADome Modulates Immune Responses.

Authors:  Valentina Audrito; Vincenzo Gianluca Messana; Lorenzo Brandimarte; Silvia Deaglio
Journal:  Front Immunol       Date:  2021-08-04       Impact factor: 7.561

8.  Study of CD27, CD38, HLA-DR and Ki-67 immune profiles for the characterization of active tuberculosis, latent infection and end of treatment.

Authors:  Sergio Díaz-Fernández; Raquel Villar-Hernández; Zoran Stojanovic; Marco Fernández; Maria Luiza De Souza Galvão; Guillermo Tolosa; Adrián Sánchez-Montalva; Jorge Abad; María Ángeles Jiménez-Fuentes; Guillem Safont; Iris Romero; Josefina Sabrià; Cristina Prat; Jose Domínguez; Irene Latorre
Journal:  Front Microbiol       Date:  2022-07-22       Impact factor: 6.064

Review 9.  NAD+ metabolism, stemness, the immune response, and cancer.

Authors:  Lola E Navas; Amancio Carnero
Journal:  Signal Transduct Target Ther       Date:  2021-01-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.